Drugs / SAXAGLIPTIN ANHYDROUS
SAXAGLIPTIN ANHYDROUS
also known as
Saxagliptin · Onglyza · BMS-477118 · - saxagliptine (Onglyza) · BMS-477118-11 · NSC-760407 · SAXA · Saxagliptin component of qternmet · +11 more
Small molecule targets DPP4
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | ONGLYZA | — | 2011-02-18 – 2024-10-11 | fda.gov ↗ |
| Approved | EU (EMA) | Onglyza | — | 2009-09-30 | europa.eu ↗ |
| Approved | US (FDA) | ONGLYZA | — | 2009-07-31 | fda.gov ↗ |
Trials 77 · started per year
today
US approved 2009
EU approved 2009
1
2
5
1
7
7
4
3
13
4
11
11
2
2
1
1
1
1
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03169959 | May → Aug 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01525225 | Sep 2012 → Jun 2013 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01662999 | Aug → Nov 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01582308 | Jun → Dec 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01441869 | Oct → Dec 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01305551 | Mar 2011 | type 2 diabetes mellitus | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT00935467 | Jul → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00770302 | Oct 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01521312 | Sep 2012 → Sep 2014 | glucose intolerance | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00857558 | Jan 2009 → Mar 2010 | type 2 diabetes mellitus | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00950599 | May 2003 → May 2004 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07033585 | Jun 2025 → Oct 2026 expected | type 2 diabetes mellitus | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02547935 | Sep 2015 → May 2018 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 332 trials | ||||||
| Phase 3 | NCT03199053 | Oct 2017 → Feb 2023 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02946632 | Dec 2016 → Dec 2019 | type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02551874 | Oct 2015 → May 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02419612 | Aug 2015 → Aug 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02315495 | Apr 2015 → Aug 2016 | type 2 diabetes mellitus | Zilin Sun | Completed | No outcome recorded |
| Phase 3 | NCT02273050 | Dec 2014 → Aug 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02284893 | Sep 2014 → Sep 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02104804 | May 2014 → Feb 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02022007 | Mar 2014 → Aug 2016 | glucose metabolism disease, polycystic ovary syndrome | Woman's | Completed | No outcome recorded |
| Phase 3 | NCT01606007 | Jul 2012 → Jan 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01619059 | Jun 2012 → Jun 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01434186 | May 2012 → Apr 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01204775 | Jun 2011 → Apr 2016 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01162876 | Jul → Nov 2010 | type 2 diabetes mellitus | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01128153 | Jun 2010 → Jun 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00960076 | Aug 2009 → Oct 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00918138 | Aug 2009 → May 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00918879 | May 2009 → Jul 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00757588 | Nov 2008 → Apr 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00683657 | Jul 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00698932 | Jun 2008 → Oct 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00661362 | Jun 2008 → Sep 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00666458 | Apr 2008 → Mar 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00614939 | Jan 2008 → Jun 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00575588 | Dec 2007 → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00374907 | Sep 2006 → Jan 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00316082 | Jun 2006 → Nov 2007 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00327015 | May 2006 → Nov 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00313313 | Apr 2006 → Sep 2007 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00295633 | Mar 2006 → Oct 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00121667 | Aug 2005 → Oct 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00121641 | Jul 2005 → Aug 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 428 trials | ||||||
| Phase 4 | NCT04445714 | Apr 2021 → Mar 2023 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT03700801 | Oct 2018 → Dec 2019 | type 2 diabetes mellitus | Zhujiang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02765204 | Mar → Dec 2016 | type 2 diabetes mellitus | Uppsala University | Completed | No outcome recorded |
| Phase 4 | NCT02605772 | Dec 2015 → Nov 2016 | type 2 diabetes mellitus | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02742233 | Nov 2015 → Oct 2017 | ulcer of lower limbs | Long Min,MD | Unknown | No outcome recorded |
| Phase 4 | NCT02583438 | Oct 2015 → Oct 2017 | obesity disorder, type 2 diabetes mellitus | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02462369 | Jun 2015 → Apr 2017 | proteinuria | The Second Hospital of Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02481479 | Jun 2015 → Aug 2018 | heart failure, type 2 diabetes mellitus | Unity Health Toronto | Completed | No outcome recorded |
| Phase 4 | NCT02407899 | Mar 2015 → Dec 2020 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02312427 | Jan 2015 → Mar 2016 | congestive heart failure, diabetes mellitus | Mitsui Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02920801 | Dec 2014 → Jul 2015 | type 2 diabetes mellitus | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02307695 | Nov 2014 → Mar 2017 | type 1 diabetes mellitus | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02243176 | Sep 2014 → Sep 2015 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02182895 | Jul 2014 → Feb 2017 | type 2 diabetes mellitus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02089438 | May 2014 → Jun 2017 | type 2 diabetes mellitus | Lund University | Completed | No outcome recorded |
| Phase 4 | NCT02104739 | Apr 2014 → Mar 2017 | obesity disorder, prediabetes syndrome | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02386943 | Dec 2013 → Mar 2015 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01960205 | Aug 2013 → Dec 2014 | prediabetes syndrome | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02285985 | Feb 2013 → Oct 2019 | type 2 diabetes mellitus | Phoenix VA Health Care System | Completed | No outcome recorded |
| Phase 4 | NCT01608724 | Nov 2012 → May 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01768208 | Oct 2012 → Dec 2016 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01660386 | Jul → Dec 2012 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01548651 | Feb 2012 → Aug 2017 | glucose intolerance | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01527747 | Jan 2012 → Nov 2024 | hypertriglyceridemia, type 2 diabetes mellitus | Oregon Health and Science University | Suspended | No outcome recorded |
| Phase 4 | NCT01107886 | May 2010 → May 2013 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01206647 | Feb 2010 → Feb 2011 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01006603 | Oct 2009 → Jun 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01006590 | Oct 2009 → Dec 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04170790 | Dec 2019 | erectile dysfunction, type 2 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
| — | NCT02148978 | Mar 2014 → Aug 2015 | cystic fibrosis | Ram Weiss | Unknown | No outcome recorded |
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT01703637 | Oct 2012 → Dec 2016 | type 2 diabetes mellitus | Lin Liao | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 32 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03933787 Comparator | Jun → Jul 2018 | disorder of catecholamine synthesis, sympathetic nervous system disorder | Eric Grouzmann | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03714594 Comparator | Jul 2018 → Aug 2022 | type 2 diabetes mellitus | University of Pisa | Completed | No outcome recorded |
| Phase 2 | NCT02597101 Background | Nov 2015 → Jun 2019 | type 2 diabetes mellitus | Nick Giannoukakis, PhD | Completed | No outcome recorded |
| Phase 2 | NCT01782261 Comparator | Feb 2012 → Feb 2015 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06107153 Comparator | Nov 2023 → Nov 2024 | type 2 diabetes mellitus | University of Basrah | Completed | No outcome recorded |
| Phase 3 | NCT03608358 Background | Feb 2019 → Aug 2020 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT02377388 Comparator | Feb 2017 → Feb 2020 | platelet aggregation, spontaneous | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02681094 Comparator | Feb 2016 → Jul 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01646320 Background | Sep 2012 → Aug 2014 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01922817 Comparator | Sep 2012 → Apr 2014 | hypoglycemia, type 1 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| Phase 3 | NCT01242228 Background | Oct 2010 → Jun 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01319357 Comparator | Oct 2010 → Apr 2013 | type 2 diabetes mellitus | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00885378 Comparator | May 2009 → Feb 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04521049 Comparator | Mar 2019 → Mar 2020 | type 2 diabetes mellitus | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT03660683 Comparator | Oct 2018 → Mar 2021 | cardiovascular disorder, type 2 diabetes mellitus | Sabyasachi Sen | Terminated | No outcome recorded |
| Phase 4 | NCT02965443 Comparator | Feb 2018 → Feb 2020 | type 2 diabetes mellitus | University Hospital Tuebingen | Terminated | No outcome recorded |
| Phase 4 | NCT03014479 Comparator | Feb → Oct 2017 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02917031 Comparator | Jan 2017 → Aug 2019 | heart failure, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02471404 Comparator | Sep 2015 → Mar 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02304081 Comparator | Jan 2015 → Aug 2016 | type 2 diabetes mellitus | Prof. Dr. Thomas Forst | Completed | No outcome recorded |
| Phase 4 | NCT02280486 Comparator | Jan 2015 → Oct 2016 | type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 4 | NCT01267448 Comparator | Sep 2014 → Jul 2015 | hyperglycemia, type 2 diabetes mellitus | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT02024477 Comparator | Nov 2013 → Sep 2017 | type 2 diabetes mellitus | George Washington University | Completed | No outcome recorded |
| Phase 4 | NCT02365233 Comparator | May 2013 → Dec 2016 | NAFLD1, type 2 diabetes mellitus | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 4 | NCT01765270 Comparator | Mar 2013 → Jun 2014 | cardiovascular disorder, type 2 diabetes mellitus | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT01552018 Comparator | Mar 2012 → Feb 2014 | coronary artery disorder, type 2 diabetes mellitus | Oslo University Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT02613897 Comparator | Jan 2016 → Jun 2018 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT02239458 Comparator | Jun 2015 → Jun 2016 | cystic fibrosis | Ram Weiss | Unknown | No outcome recorded |
| — | NCT02244164 Comparator | Oct 2014 → Feb 2023 | type 2 diabetes mellitus | Erasme University Hospital | Terminated | No outcome recorded |
| — | NCT02969798 Comparator | Jan 2014 → Dec 2026 expected | glucose intolerance, prediabetes syndrome, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-03-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Obtains Marketing Approval in Japan for Onglyza Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin® otsuka.co.jp ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 112 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAXAGLIPTIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | - saxagliptine (Onglyza) | “- saxagliptine (Onglyza®)” NCT02244164 ↗ |
| Known as | BMS-477118 | “The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated...” NCT01606007 ↗2“hydroxyadamantyl compound BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor” PMID 16033281 ↗ Jul 2005 “Saxagliptin (BMS-477118)” NCT01434186 ↗ |
| Known as | BMS-477118-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | NSC-760407 | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Onglyza | “Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50...” NCT04521049 ↗4“Onglyza® (saxagliptin) 5 mg” NCT07033585 ↗ “Onglyza (saxagliptin)” NCT01441869 ↗ “Saxagliptin, Onglyza” NCT02551874 ↗ “Onglyza” NCT02243176 ↗ |
| Known as | SAXA | “dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA)” PMID 28228317 ↗ Oct 2016 |
| Known as | Saxagliptin | “DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured.” NCT02312427 ↗107“The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment” PMID 27402391 ↗ Jul 2016 “Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors” NCT06449235 ↗ “Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin” NCT03014479 ↗ “A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus” NCT01162876 ↗ “Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg” NCT02946632 ↗ “Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day” NCT02365233 ↗ “Metformin, Dapagliflozin and Saxagliptin” NCT03700801 ↗ “saxagliptin (2.5-5mg daily)” NCT02528019 ↗ “Drug: Saxagliptin” NCT03199053 ↗ |
| Known as | Saxagliptin component of qternmet | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | SAXAGLIPTIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin hydrochloride component of kombiglyze | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin hydrochloride component of qtern | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin hydrochloride component of qternmet xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | Saxagliptin/Metformin XR FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01305551 ↗ |
| Known as | Saxagliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Known as | saxagliptine | “- saxagliptine (Onglyza®)” NCT02244164 ↗ |
| Known as | SBMS-477118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL385517 ↗ |
| Action | Inhibit | “dipeptidyl peptidase-4 inhibitor saxagliptin” PMID 27402391 ↗ Jul 2016 |
| Modality | Small molecule | — CHEMBL385517 ↗ |
| Route | Oral | “Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)” NCT00121667 ↗ |
| Target | DPP4 | “dipeptidyl peptidase-4 inhibitor” PMID 27402391 ↗ Jul 2016 |